

CITATION REPORT

List of articles citing

Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension

DOI: 10.1016/j.amjhyper.2005.05.014

American Journal of Hypertension, 2005, 18, 1422-8.

Source: <https://exaly.com/paper-pdf/39409458/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
322	Masked hypertension: a common but insidious presentation of hypertension. 2006 , 22, 617-20		16
321	Ambulatory blood-pressure monitoring. 2006 , 354, 2368-74		644
320	Cardiovascular risk in patients receiving double therapy with false and true nonresponder hypertension. 2006 , 11, 303-7		4
319	Predictive factors for masked hypertension within a population of controlled hypertensives. 2006 , 24, 2365-70		57
318	The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease. 2006 , 70, 1000-7		63
317	New drugs for hypertension: what do they offer?. 2006 , 8, 425-32		8
316	Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension. 2007 , 21, 212-9		15
315	Chapter 1: Introduction. 2007 , 14, S2-S113		
314	Effectiveness of blood pressure control outside the medical setting. <i>Hypertension</i> , 2007 , 49, 62-8	8.5	142
313	Masked hypertension: a review. 2007 , 30, 479-88		162
312	Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. 2007 , 25, 2193-8		337
311	Cardiovascular risk prediction based on home blood pressure measurement: the Didima study. 2007 , 25, 1590-6		76
310	Do we need out-of-office blood pressure in every patient?. 2007 , 22, 321-8		15
309	Masked hypertension: an independent predictor of organ damage. 2007 , 25, 275-9		13
308	Aldosterone excess and resistance to 24-h blood pressure control. 2007 , 25, 2131-7		29
307	Mesure ambulatoire de la pression artérielle. 2007 , 2, 1-8		
306	Ambulatory blood pressure monitoring as an investigative tool for characterizing resistant hypertension and its rational treatment. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 25-30	2.3	7

305	Masked hypertension definition, impact, outcomes: a critical review. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 956-63	2.3	47
304	Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 7-12	2.3	23
303	Practical advice for home blood pressure measurement. 2007 , 23, 577-80		8
302	[Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]. 2007 , 129, 1-5		27
301	Out-of-Office Blood Pressure Monitoring. 2007 , 535-555		
300	An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. 2007 , 33, 414-21		97
299	Should we use ambulatory blood pressure monitoring to guide therapy?. 2008 , 2, 274-279		1
298	Resistant hypertension: an overview of evaluation and treatment. 2008 , 52, 1749-57		253
297	Is the use of ABPM justified in patients on 1 or 2 antihypertensive medications?. 2008 , 125, 118-9		
296	Antiendothelial cell antibody levels in patients with masked hypertension. 2008 , 130, 405-8		4
295	[Masked hypertension: myth or reality?]. 2008 , 37, 1034-7		3
294	Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. 2008 , 121, S2-7		27
293	Prognostic relevance of masked hypertension in subjects with prehypertension. <i>American Journal of Hypertension</i> , 2008 , 21, 879-83	2.3	42
292	Control de la presi3n arterial, concordancias y discrepancias entre diferentes m3odos de medida utilizados. 2008 , 25, 231-239		1
291	Control de la presi3n arterial, concordancias y discrepancias entre diferentes m3odos de medida utilizados. 2008 , 25, 231-239		1
290	Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. <i>Hypertension</i> , 2008 , 51, 1403-19	8.5	1136
289	Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. 2008 , 117, e510-26		895
288	Masked hypertension: a systematic review. 2008 , 26, 1715-25		194

287	The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study. 2008 , 26, 699-705		33
286	Masked hypertension in obstructive sleep apnea syndrome. 2008 , 26, 885-92		89
285	Clinical approach in treatment of resistant hypertension. 2009 , 2, 9-23		3
284	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. <i>Hypertension</i> , 2009 , 54, 188-95	8.5	51
283	Changes of metalloproteinases profile in patients with masked hypertension. 2009 , 60, 757-62		1
282	Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 61-5	2.3	20
281	Characterization and treatment of resistant hypertension. 2009 , 11, 407-13		28
280	Ambulatory blood pressure monitoring in childhood and adult obesity. 2009 , 11, 133-42		7
279	[Differences between office and ambulatory control of hypertension in very elderly patients. The CARDIORISC - MAPAPRES project]. 2009 , 133, 769-76		19
278	Reduction of blood pressure in patients with treatment-resistant hypertension. 2009 , 10, 2959-71		3
277	Current options for the treatment of resistant hypertension. 2009 , 7, 1385-93		4
276	Resistant hypertension. 2009 , 25, 315-7		7
275	Out-of-office blood pressure monitoring in chronic kidney disease. 2009 , 14, 2-11		58
274	Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. 2010 , 15, 1-7		28
273	Tom Pickering as a clinical scientist: masked hypertension. 2010 , 15, 85-9		6
272	Ambulatory blood pressure monitoring in primary care. 2010 , 103, 447-52		9
271	Masked hypertension: evidence of the need to treat. 2010 , 12, 349-55		47
270	Clinical implications of ambulatory and home blood pressure monitoring. 2010 , 40, 423-31		10

269	Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. 2010 , 24, 64-73		20
268	Urinary albumin excretion is associated with true resistant hypertension. 2010 , 24, 27-33		47
267	Treatment of resistant hypertension. 2010 , 28, 2194-5		12
266	Papel de la MAPA en el manejo de la hipertensi3n arterial resistente. 2010 , 27, 34-40		
265	Masked hypertension: evaluation, prognosis, and treatment. <i>American Journal of Hypertension</i> , 2010 , 23, 941-8	2.3	78
264	The association of masked hypertension in treated type 2 diabetic patients with carotid artery IMT. 2010 , 89, 239-42		7
263	Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. 2010 , 28, 639-54		46
262	Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. <i>Hypertension</i> , 2011 , 57, 898-902	8.5	547
261	Masked hypertension unfavourably affects haemostasis parameters. 2011 , 20, 218-21		2
260	[Prevalence of masked hypertension in a cohort of controlled hypertensive patients in Spain]. 2011 , 136, 607-12		6
259	Ambulatory blood pressure monitoring in resistant hypertension. 2011 , 2011, 285612		8
258	Benefits from treatment and control of patients with resistant hypertension. 2010 , 2011, 318549		12
257	Common secondary causes of resistant hypertension and rational for treatment. 2011 , 2011, 236239		49
256	Aldosteronism and resistant hypertension. 2011 , 2011, 837817		23
255	Detection of masked hypertension and the 'mask effect' in patients with well-controlled office blood pressure. 2011 , 75, 357-65		15
254	[Differences in the degree of control of arterial hypertension according to the measurement procedure of blood pressure in patients [65 years. FAPRES study]. 2011 , 211, 76-84		4
253	Management of Resistant Hypertension. 2011 , 5, 373-382		1
252	Subtypes of resistant hypertension based on out-of-office blood pressure measurement. <i>Hypertension</i> , 2011 , 58, e28	8.5	2

251	Measured blood pressure and hypertension among young adults: a comparison between two nationally representative samples. 2011 , 57, 184-99		5
250	Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. 2011 , 25, 656-64		33
249	Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. <i>American Journal of Hypertension</i> , 2011 , 24, 52-8	2.3	251
248	Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. <i>Hypertension</i> , 2011 , 57, 556-60	8.5	41
247	Renal denervation: ultima ratio or standard in treatment-resistant hypertension. <i>Hypertension</i> , 2012 , 60, 596-606	8.5	76
246	Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. <i>Hypertension</i> , 2012 , 59, 384-9	8.5	39
245	The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. <i>Hypertension</i> , 2012 , 60, 303-9	8.5	67
244	Home versus ambulatory blood pressure monitoring in the diagnosis of clinic resistant and true resistant hypertension. 2012 , 26, 696-700		32
243	Abnormalities of vascular function in resistant hypertension. 2012 , 21, 104-9		14
242	Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. 2012 , 10, 735-45		15
241	Can ambulatory blood pressure measurements substitute assessment of subclinical cardiovascular damage?. 2012 , 30, 513-21		7
240	Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. 2012 , 21, 31-8		53
239	Incidence and prognosis of resistant hypertension in hypertensive patients. 2012 , 125, 1635-42		608
238	Resistant hypertension, obstructive sleep apnoea and aldosterone. 2012 , 26, 281-7		101
237	Resistant hypertension and aldosterone: an update. 2012 , 28, 318-25		41
236	Refractory hypertension: definition, prevalence, and patient characteristics. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 7-12	2.3	135
235	Ambulatory blood pressure monitoring: from old concepts to novel insights. 2012 , 44, 173-82		18
234	Use of ambulatory blood pressure monitoring to guide hypertensive therapy. 2013 , 15, 746-60		4

233	Resistant hypertension and target organ damage. 2013 , 36, 485-91		50
232	Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension. 2013 , 61, 222-6		16
231	Ambulatory blood pressure monitoring: is it mandatory for blood pressure control in treated hypertensive patients?: prospective observational study. 2013 , 168, 2255-63		13
230	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. 2013 , 34, 2132-40		230
229	Resistant Hypertension. 2013 , 501-509		
228	Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. 2013 , 88, 1099-107		122
227	Renal sympathetic denervation for treatment of resistant hypertension - indigenous technique. 2013 , 65, 239-42		3
226	Poor sleep quality and resistant hypertension. 2013 , 14, 1157-63		71
225	[Renal sympathetic denervation in refractory hypertension]. 2013 , 140, 263-5		2
224	Epidemiology, prognosis, and treatment of resistant hypertension. 2013 , 33, 1071-86		10
223	How to use ambulatory blood pressure monitoring in resistant hypertension. 2013 , 36, 385-9		22
222	Profile of ambulatory blood pressure in resistant hypertension. 2013 , 36, 565-9		8
221	Urinary albumin excretion at follow-up predicts cardiovascular outcomes in subjects with resistant hypertension. <i>American Journal of Hypertension</i> , 2013 , 26, 1148-54	2.3	9
220	Prevalence and clinical profile of resistant hypertension among treated hypertensive subjects. 2013 , 35, 412-7		4
219	European Society of Hypertension position paper on ambulatory blood pressure monitoring. 2013 , 31, 1731-68		898
218	Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. 2013 , 31, 2094-102		94
217	Resistant hypertension. 2013 , 252-269		
216	Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. <i>Hypertension</i> , 2013 , 62, 691-7	8.5	98

215	Divergent retinal vascular abnormalities in normotensive persons and patients with never-treated, masked, white coat hypertension. <i>American Journal of Hypertension</i> , 2013 , 26, 318-25	2.3	38
214	Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 333-6	2.3	32
213	The human side of failed hypertension treatment. <i>Journal of Clinical Hypertension</i> , 2013 , 15, 762-4	2.3	0
212	Prevalence of resistant hypertension in 1810 patients followed up in a specialized outpatient clinic and its association with the metabolic syndrome. 2013 , 22, 307-11		5
211	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. 2013 , 34, 1204-14		128
210	Job strain and ambulatory blood pressure: a meta-analysis and systematic review. 2013 , 103, e61-71		137
209	Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study. 2013 , 31, 610-5; discussion 615		18
208	Clinical situations associated with difficult-to-control hypertension. 2013 , 31 Suppl 1, S3-8		15
207	An overlooked cause of resistant hypertension: upper airway resistance syndrome - preliminary results. 2014 , 69, 731-4		5
206	Resistant hypertension, patient characteristics, and risk of stroke. 2014 , 9, e104362		17
205	Non-interventional management of resistant hypertension. 2014 , 6, 1080-90		4
204	Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. 2014 , 3, e001398		24
203	Left ventricular diastolic function evaluated by the E/e' ratio is impaired in patients with masked uncontrolled hypertension. 2014 , 36, 538-44		4
202	Apparent and true resistant hypertension: definition, prevalence and outcomes. 2014 , 28, 463-8		133
201	Use of ambulatory blood pressure measurement in the definition of resistant hypertension: a review of the evidence. 2014 , 37, 967-72		25
200	Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. 2014 , 12, 623-34		14
199	Assessment and management of resistant hypertension. 2014 , 186, E689-97		8
198	Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. 2014 , 28, 213-7		47

197	Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. 2014 , 34, 483-91		18
196	Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. 2014 , 34, 532-9		10
195	Adipokines: novel players in resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 754-9	2.3	22
194	The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010. 2014 , 8, 891-7		23
193	Hypertension: treatment-resistant hypertension - a risk factor for ESRD. 2014 , 10, 189-90		1
192	Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. <i>Hypertension</i> , 2014 , 64, 989-96	8.5	112
191	Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study. 2014 , 3, e000660		44
190	Baroreflex activation therapy for patients with drug-resistant hypertension. 2014 , 12, 955-62		6
189	The white-coat effect is an independent predictor of myocardial ischemia in resistant hypertension. 2014 , 23, 276-80		10
188	Role of aldosterone blockade in resistant hypertension. 2014 , 34, 273-84		21
187	The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. 2014 , 34, 247-56		19
186	Hipertensi arterial resistente. 2014 , 31, 58-65		0
185	Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. 2014 , 29, 1327-35		16
184	Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. <i>Hypertension</i> , 2014 , 64, 118-24	8.5	110
183	Cardiovascular and renal complications in patients with resistant hypertension. 2014 , 16, 471		22
182	Resistant or refractory hypertension: are they different?. 2014 , 16, 485		15
181	Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. <i>Hypertension</i> , 2014 , 63, 451-8	8.5	124
180	Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. 2014 , 35, 1801-8		10

179	Clinical characteristics of resistant hypertension evaluated by ambulatory blood pressure monitoring. 2014 , 36, 454-8	4
178	Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study. 2014 , 15, 131	12
177	Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. 2014 , 433, 179-83	26
176	Obstructive sleep apnea syndrome as a cause of resistant hypertension. 2014 , 37, 601-13	50
175	Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk. 2014 , 16, 445	5
174	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. 2014 , 32, 415-22	59
173	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. 2014 , 32, 635-43	67
172	Beauty in Simplicity: Abnormal Neutrophil to Lymphocyte Ratio in Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 538-40	2.3 2
171	Carotid Baroreceptor Stimulation and Arteriovenous Shunts for Resistant Hypertension. 2015 , 11, 223-7	3
170	Mineralocorticoid Receptor Antagonists Therapy in Resistant Hypertension: Time to Implement Guidelines!. 2015 , 2, 3	5
169	Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension. 2015 , 105, 168-75	4
168	An update on renal artery denervation and its clinical impact on hypertensive disease. 2015 , 2015, 607079	5
167	Masked Hypertension: Does It Lead to CVD or CKD?. 2015 , 101-109	
166	Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. 2015 , 9, 397-402	31
165	Improvement of resistant hypertension by nocturnal hemodialysis in a patient with end-stage kidney disease. 2015 , 5, 60-5	
164	[Systematic screening of masked hypertension in patients with peripheral arterial disease: a pilot study]. 2015 , 40, 10-7	0
163	Resistant hypertension: do all definitions describe the same patients?. 2015 , 29, 530-4	6
162	Central arteriovenous anastomosis in resistant hypertension?. 2015 , 385, 1596-7	5

161	Resistant hypertension: a volemic or nervous matter?. 2015 , 9, 408-9		5
160	Prevalence of masked uncontrolled hypertension according to the number of office blood pressure measurements. 2015 , 215, 425-30		5
159	The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. <i>American Journal of Hypertension</i> , 2015 , 28, 1376-85	2.3	71
158	Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. 2015 , 75, 473-85		12
157	Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. 2015 , 88, 622-32		98
156	Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology. 2015 , 3, e12476		27
155	Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. 2015 , 101, 10-6		32
154	Lifestyle modification for resistant hypertension: The TRIUMPH randomized clinical trial. 2015 , 170, 986-994.e523		
153	Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?. 2015 , 17, 78		11
152	Reducing women's cardiovascular disease risk profile. 2015 , 11, 385-97		2
151	Prevalence of masked uncontrolled hypertension according to the number of office blood pressure measurements. 2015 , 215, 425-430		
150	White coat effect and masked uncontrolled hypertension in treated hypertensive-diabetic patients: Prevalence and target organ damage. 2015 , 7, 699-707		6
149	Resistant hypertension: medical management and alternative therapies. 2015 , 33, 75-87		7
148	Prevalence of white-coat and masked hypertension in national and international registries. 2015 , 38, 1-7		72
147	Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. <i>American Journal of Hypertension</i> , 2015 , 28, 355-61	2.3	109
146	An update on the pharmacogenetics of treating hypertension. 2015 , 29, 283-91		26
145	Tertiary work-up of apparent treatment-resistant hypertension. 2016 , 25, 312-8		11
144	Acute Sildenafil Use Reduces 24-Hour Blood Pressure Levels in Patients With Resistant Hypertension: A Placebo-Controlled, Crossover Trial. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1168-1172 ^{2,3}		3

143	Ambulatory Blood Pressure Parameters and Heart Failure With Reduced or Preserved Ejection Fraction in Elderly Treated Hypertensive Patients. <i>American Journal of Hypertension</i> , 2016 , 29, 1001-7	2-3	11
142	Resistant Hypertension: An Incurable Disease or Just a Challenge For Our Medical Skill?. 2016 , 23, 347-353		1
141	A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. 2016 , 10, 510-516.e1		10
140	Globalization, Work, and Cardiovascular Disease. 2016 , 46, 656-92		66
139	Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension. 2016 , 18, 112		19
138	Blood Pressure Control Provides Less Cardiovascular Protection in Adults With Than Without Apparent Treatment-Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 817-24	2-3	15
137	Baroreceptor Stimulation for Resistant Hypertension. <i>American Journal of Hypertension</i> , 2016 , 29, 1319-1324		8
136	Deregulation of Soluble Adhesion Molecules in Resistant Hypertension and Its Role in Cardiovascular Remodeling. 2016 , 80, 1196-201		12
135	Unilateral Carotid Body Resection in Resistant Hypertension: An Exciting First Step Toward a New Therapy?. 2016 , 1, 325-327		1
134	Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. 2016 , 21, 1486-1492		10
133	Prognostic Importance of Ambulatory Blood Pressure Monitoring in Resistant Hypertension: Is It All that Matters?. 2016 , 18, 85		10
132	Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 1162-1167	2-3	7
131	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. 2016 , 25, 996-1003		12
130	Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients. 2016 , 39, 805-811		32
129	Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. 2016 , 10, 307-17		20
128	Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. 2016 , 129, 661-6		24
127	Ambulatory Blood Pressure Monitoring in Coronary Artery Disease and Heart Failure. 2016 , 299-321		
126	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. 2016 , 18, 6		28

125	The use of positive airway pressure therapy for treatment of resistant hypertension. 2016 , 14, 505-11		1
124	Prognostic Value of Ambulatory Blood Pressure Monitoring. 2016 , 165-191		
123	Prevalence and determinants of white coat effect in a large UK hypertension clinic population. 2016 , 30, 386-91		16
122	Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. 2016 , 30, 191-6		13
121	Current approach to masked hypertension: From diagnosis to clinical management. 2017 , 44, 1272-1278		6
120	Present and Future of Interventional Treatment of Resistant Hypertension. 2017 , 19, 4		5
119	[Resistant or refractory arterial hypertension?]. 2017 , 34, 1-3		
118	Metabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 592-600	2.3	14
117	Work, Stress, and Cardiovascular Disease. 2017 , 97-124		2
116	Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. 2017 , 35, 1133-1144	55	
115	Matrix metalloproteinase-2 -735C/T polymorphism is associated with resistant hypertension in a specialized outpatient clinic in Brazil. 2017 , 620, 23-29		9
114	White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. 2017 , 35, 677-688		107
113	Utility of ambulatory blood pressure monitoring for the management of hypertension. 2017 , 32, 365-372		5
112	Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial. 2017 , 18, 124		3
111	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. <i>Hypertension</i> , 2017 , 70, 1099-1105	8.5	31
110	Pharmacotherapy for resistant hypertension in adults. 2017 ,		78
109	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. 2017 , 40, 1273-1284		312
108	Resistant Hypertension and Outcomes in Patients with and Without Chronic Kidney Disease. 2017 , 59-75		

107	Risk Stratification of Resistant Hypertension in Chronic Kidney Disease. 2017 , 77-88		
106	Prognosis of Masked and White Coat Uncontrolled Hypertension Detected by Ambulatory Blood Pressure Monitoring in Elderly Treated Hypertensive Patients. <i>American Journal of Hypertension</i> , 2017 , 30, 1106-1111	2.3	24
105	Diagnosis and management of resistant hypertension. 2017 , 103, 1295-1302		17
104	Prognostic Value of Nondipping and Morning Surge in Elderly Treated Hypertensive Patients With Controlled Ambulatory Blood Pressure. <i>American Journal of Hypertension</i> , 2017 , 30, 159-165	2.3	11
103	Investigation and management of adult hypertension. 2018 , 104, 1543-1551		1
102	Sleep Disturbances/Sleep Apnea. 2018 , 259-287		
101	Resistant hypertension: Renal denervation or intensified medical treatment?. 2018 , 50, 6-11		11
100	The rs243866/243865 polymorphisms in MMP-2 gene and the relationship with BP control in obese resistant hypertensive subjects. 2018 , 646, 129-135		7
99	Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?. 2018 , 20, 26		5
98	Clinical hypertension: Blood pressure variability. 2018 , 64, 5-13		3
97	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. 2018 , 8, e021038		20
96	Prognostic Value of Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2018 , 72, 862-869	8.5	61
95	Masked uncontrolled hypertension: Prevalence and predictors. 2018 , 70, 369-373		5
94	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. <i>Hypertension</i> , 2018 , 72, e53-e90	8.5	333
93	The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions. 2018 , 20, 60		4
92	Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. 2019 , 105, 98-105		89
91	Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. 2019 , 42, 1708-1715		13
90	The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension. 2019 , 21, 57		2

89	Resistant Hypertension: Diagnosis and Management. 2019 , 26, 99-109		4
88	Patient with Resistant Hypertension. 2019 , 53-65		
87	Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis. 2019 , 170, 853-862		64
86	Mūchhausen Syndrome as an Unusual Cause of Pseudo-resistant Hypertension: A Case Report. 2019 , 14, 792-796		
85	A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure. 2019 , 37, 1775-1785		21
84	Does treatment-resistant hypertension exist in children? A review of the evidence. 2020 , 35, 969-976		4
83	Erucin exhibits vasorelaxing effects and antihypertensive activity by H S-releasing properties. 2020 , 177, 824-835		29
82	Masked Hypertension: A Systematic Review. 2020 , 29, 102-111		15
81	Prediction of the early response to spironolactone in resistant hypertension by the combination of matrix metalloproteinase-9 activity and arterial stiffness parameters. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,		6.4
80	Bariatric Surgery for Resistant Hypertension: Working in Progress!. 2020 , 22, 55		2
79	Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 2093-2102	2.3	6
78	Prognostic Value of Masked Uncontrolled Hypertension Defined by Different Ambulatory Blood Pressure Criteria. <i>American Journal of Hypertension</i> , 2020 , 33, 726-733	2.3	7
77	Prognostic Importance of On-Treatment Clinic and Ambulatory Blood Pressures in Resistant Hypertension: A Cohort Study. <i>Hypertension</i> , 2020 , 75, 1184-1194	8.5	10
76	Resistant Hypertension in a Dialysis Patient. <i>Hypertension</i> , 2020 , 76, 278-287	8.5	0
75	Ambulatory blood pressure monitoring over 24 h: A Latin American Society of Hypertension position paper-accessibility, clinical use and cost effectiveness of ABPM in Latin America in year 2020. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 527-543	2.3	9
74	Treatment resistant hypertension among ambulatory hypertensive patients: A cross sectional study. 2020 , 15, e0232254		0
73	Long-term Effect of CPAP Treatment on Cardiovascular Events in Patients With Resistant Hypertension and Sleep Apnea. Data From the HIPARCO-2 Study. 2021 , 57, 165-171		6
72	Office blood pressure threshold of 130/80 mmHg better predicts uncontrolled out-of-office blood pressure in apparent treatment-resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 595-605 ^{2,3}		1

71	Targeting blood pressure for stroke prevention: current evidence and unanswered questions. 2021 , 268, 785-795		7
70	Resistant hypertension: Prevalence and profile of patients followed in a university ambulatory. 2021 , 9, 20503121211020892		
69	Risk of Target Organ Damage in Patients with Masked Hypertension versus Sustained Hypertension: A Meta-analysis. 2021 , 5, 155-163		0
68	Time to recognize continuous positive airway pressure as a blood pressure-lowering treatment in patients with obstructive sleep apnoea and resistant hypertension?. 2021 , 39, 234-235		
67	Long-term Effect of CPAP Treatment on Cardiovascular Events in Patients With Resistant Hypertension and Sleep Apnea. Data From the HIPARCO-2 Study. 2021 , 57, 165-171		2
66	Prognostic value of masked uncontrolled apparent resistant hypertension detected through home blood pressure monitoring. 2021 , 39, 2141-2146		2
65	Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension. <i>Journal of Clinical Hypertension</i> , 2021 , 23, 1363-1371	2.3	1
64	Apparent treatment resistant hypertension and the risk of recurrent cardiovascular events and mortality in patients with established vascular disease. 2021 , 334, 135-141		4
63	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. 2021 , 44, 1471-1482		3
62	Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. 2021 , 10, e019434		4
61	Ambulatory Monitoring of Blood Pressure: An Overview of Devices, Analyses, and Clinical Utility. 2016 , 55-76		1
60	Primary and Secondary Hypertension. 2012 , 1670-1751		1
59	The HIPARCO-2 study: long-term effect of continuous positive airway pressure on blood pressure in patients with resistant hypertension: a multicenter prospective study. 2021 , 39, 302-309		10
58	Primary aldosteronism: a common cause of resistant hypertension. 2017 , 189, E773-E778		24
57	Clinical Diagnosis and Management of Resistant Hypertension. 2016 , 11, 12-17		3
56	Renal Sympathetic Denervation - A Review of Applications in Current Practice. 2014 , 9, 54-61		5
55	Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. 2019 , 69-82		27
54	A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. 2006 , 2, 195-201		25

53	Management of resistant hypertension. 2011 , 53, 423-428	1
52	Brazilian Position Statement on Resistant Hypertension - 2020. 2020 , 114, 576-596	2
51	Prevalence, predictive factor, and clinical significance of white-coat hypertension and masked hypertension in Korean hypertensive patients. 2007 , 22, 256-62	19
50	Updated ESH position paper on interventional therapy of resistant hypertension. 2013 , 9 Suppl R, R58-66	54
49	Assessment of Mean Platelet Volume in Patients with Resistant Hypertension, Controlled Hypertension and Normotensives. 2015 , 47, 79-84	11
48	Prevalence and Risk Factors for Resistant Hypertension: Cross-Sectional Study From a Tertiary Care Referral Hospital in South India. 2021 , 13, e18779	0
47	Association of treatment-resistant hypertension defined by home blood pressure monitoring with cardiovascular outcome. 2021 ,	7
46	Masked inefficacy of arterial hypertension treatment: prevalence and predictors. 2011 , 10, 11-17	0
45	Predictors of insufficient response to initial antihypertensive treatment. 2011 , 17, 525-530	
44	Effects of perindopril/indapamide fixed high dose combination on ambulatory blood pressure in subjects with previously uncontrolled arterial hypertension. 2012 , 18, 505-513	0
43	Primary aldosteronism and resistant arterial hypertension. 2012 , 18, 514-521	2
42	24-hour Ambulatory BP Monitoring and Home BP Measurements in Resistant Hypertension. 2013 , 95-105	0
41	False Versus True Resistant Hypertension. 2013 , 59-75	2
40	Cardiac and Vascular Alterations in Resistant Hypertension. 2013 , 39-50	
39	Follow-up of Patients with Resistant Hypertension. 2013 , 155-169	
38	Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. 2015 , 104, 85-9	2
37	[Renal sympathetic denervation in treatment-resistant hypertension]. 2014 , 134, 32-6	0
36	Treatment resistant hypertension--investigation and conservative management. 2014 , 111, 425-31	12

- 35 White Coat Hypertension and Cardiovascular Morbidity and Mortality. **2015**, 113-122
- 34 NephroBlate™ Renal Denervation System: Urologic-Nephrologic Based Approach to Resistant Hypertension. **2015**, 125-134 ○
- 33 White Coat Hypertension: To Treat or Not to Treat. **2015**, 123-135
- 32 Sleep Apnea. **2016**, 89-118
- 31 Adult Patient with Pseudo-Resistant Hypertension: Spurious Resistant Hypertension. **2016**, 75-90
- 30 Resistant Hypertension: A Real Entity Requiring Special Treatment?. **2016**, 11, 8-11
- 29 Resistant Hypertension in Chronic Kidney Disease. **2016**, 85-105
- 28 White-Coat and Masked Hypertension. **2018**, 104-114
- 27 Treatment of Resistant Hypertension. **2018**, 639-652
- 26 Clinical Characteristics Associated with Electrocardiographic Left Ventricular Hypertrophy in Clinical Normotensives without a History of Hypertension: a Cross-Sectional Study. **2019**, 40, 106-115
- 25 Cardiac pathology in patients with resistant hypertension. **2019**, 34, 53-59
- 24 Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease-A Report from the Chronic Renal Insufficiency Cohort Study. **2020**, 1, 810-818 ○
- 23 Diagnosis and treatment of arterial hypertension 2021. **2021**, 5
- 22 Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study. *Hypertension*, **2021**, 78, 1781-1790 8.5 6
- 21 Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology. *Anatolian Journal of Cardiology*, **2020**, 24, 137-152 0.8 ○
- 20 Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient.. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2022**, 8, 1-3 6.4
- 19 Is Arterial Pressure Self-Measurement Better Than Ambulatory 24-Hour Pressure Monitoring?. **2007**, 417-423
- 18 Ambulatory Monitoring of Blood Pressure. **2007**, 73-95

17	Risk of Atrial Fibrillation in Masked and White Coat Uncontrolled Hypertension. <i>American Journal of Hypertension</i> , 2021 , 34, 504-510	2.3	1
16	Management of Resistant Hypertension: Do Not Give Up on Medication. <i>Nephrology Self-assessment Program: NephSAP</i> , 2014 , 13, 57-63	0	4
15	Prognostic value of non-resistant and resistant masked uncontrolled hypertension detected by ambulatory blood pressure monitoring.. <i>Journal of Clinical Hypertension</i> , 2022 ,	2.3	0
14	K�m�z h�re da�th geni�k �ile diren� hipertansiyon aras�daki ili�ki. <i>Turkish Journal of Clinics and Laboratory</i> ,	0	
13	Pseudo and resistant hypertension: A chaotic perspective.. <i>Journal of Clinical Hypertension</i> , 2022 ,	2.3	0
12	The Relationship Between Racial/Ethnic Concordance and Hypertension Control.. 2021 , 25,		0
11	Association of Nighttime Masked Uncontrolled Hypertension With Left Ventricular Hypertrophy and Kidney Function Among Patients with Chronic Kidney Disease Not Receiving Dialysis. <i>JAMA Network Open</i> , 2022 , 5, e2214460	10.4	2
10	INSUFFICIENT CONTROL OF OUT-OF-OFFICE BLOOD PRESSURE: THE PROBLEM OF MASKED UNCONTROLLED HYPERTENSION: review. <i>Inter Collegas</i> , 2022 , 8, 201-210		
9	Chaos, resistant and pseudoresistant hypertension � thousands of butterflies in the BP control system � 2022 , 9, 006-010		
8	The Role of Ambulatory Blood Pressure Monitoring in Current Clinical Practice. 2022 ,		1
7	Renal Denervation for Resistant Hypertension: A Concise Update on Treatment Options and the Latest Clinical Evidence. 2022 , 11, 385-392		
6	Sustained Activation of CLR/RAMP Receptors by Gel-Forming Agonists. 2022 , 23, 13408		0
5	Hypertension Care: It's Time to Act. 2-10		0
4	Prediction of Masked Uncontrolled Hypertension Detected by Ambulatory Blood Pressure Monitoring. 2022 , 12, 3156		1
3	Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US. 2023 , e13258		0
2	What is resistant arterial hypertension?. 2023 , 32,		0
1	Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension. 2023 , 13, 806		0